ADC Therapeutics SA
ADCT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771910
No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding ADC Therapeutics SA changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 37 | 74 | +37 |
| Shares | 34.7M | 51.8M | +17.1M (+49.4%) |
| Value | $155.8M | $163.7M | +$7.90M (+5.1%) |
New holders (45)
Institutions that held ADC Therapeutics SA at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (8)
Institutions that held ADC Therapeutics SA at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $4.49M |
| Monashee Investment Management LLC | 500,000 | $2.25M |
| Marshall Wace, LLP | 243,243 | $1.09M |
| Cubist Systematic Strategies, LLC | 120,775 | $542.3K |
| Hennion & Walsh Asset Management, Inc. | 70,636 | $317.2K |
| Balyasny Asset Management LLC | 23,765 | $106.7K |
| Lynx Capital Group Ltd | 15,000 | $67.3K |
| Group One Trading, L.P. | 4,787 | $21.5K |